MOSAIC: A model to assess the cost-effectiveness of dexamethasone for admitted COVID-19 patients in South Africa

MODEL STRATEGIESThis model assesses costs and outcomes for admitted severe and critical Covid-19 patients from time of admission to discharge or death.<br>Two competing strategies are modelled:1. The "status quo" summarizes costs and outcomes for patients assuming usual care (no dexamethasone).2. The "dexamethasone" comparator summarizes costs and outcomes for patients assuming usual care with dexamethasone at 6mg/day over 10 days. <br>MODEL OUTCOMESCost: mean cost (general ward and ICU) per admitted patient from the health care provider's perspective.Health outcomes: mean DALYs and deaths per admitted patient. Other: mean ICU days and inpatient days per admitted patient.